Towards an individualized management of pubertal induction in girls with hypogonadism: insight into the best replacement outcomes from a large multicentre registry.


Journal

European journal of endocrinology
ISSN: 1479-683X
Titre abrégé: Eur J Endocrinol
Pays: England
ID NLM: 9423848

Informations de publication

Date de publication:
07 Jun 2023
Historique:
received: 18 01 2023
revised: 08 03 2023
accepted: 05 04 2023
medline: 15 6 2023
pubmed: 26 5 2023
entrez: 26 5 2023
Statut: ppublish

Résumé

An evidence-based pubertal induction scheme in hypogonadal girls is still to be established. Interestingly, literature data report a suboptimal uterine longitudinal diameter (ULD) in >50% of treated hypogonadal women, negatively influencing their pregnancy outcomes. This study aims to investigate auxological and uterine outcomes of pubertal induction in girls in the light of underlying diagnosis and therapeutic schemes used. Retrospective analysis of longitudinal data from a multicentric registry. Auxological, biochemical, and radiological data were collected at baseline and during follow-up in 95 hypogonadal girls (chronological age > 10.9 years, Tanner stage ≤ 2) treated with transdermal 17β-oestradiol patches for at least 1 year. Induction was started at a median dose of 0.14 mcg/kg/day with a 6-monthly increase and was considered completed for 49/95 patients who started progesterone with a concomitant oestrogen adult dose. At the end of induction, the achievement of the complete breast maturation was associated with a 17β-oestradiol dose at progesterone introduction. ULD showed a significant correlation with a 17β-oestradiol dosage. Final ULD was >65 mm in only 17/45 girls. At multiple regression analysis, pelvic irradiation represented the major determinant of reduced final ULD. After correction for uterine irradiation, ULD was associated with the 17β-oestradiol dose at progesterone introduction. Final ULD was not significantly different from the one assessed after progesterone introduction. Our results provide evidence that progestins, hampering further changes in uterine volume and breast development, should be introduced only in the presence of a concomitant adequate 17β-oestradiol dose and an appropriate clinical response.

Identifiants

pubmed: 37232247
pii: 7180093
doi: 10.1093/ejendo/lvad056
doi:

Substances chimiques

Progesterone 4G7DS2Q64Y
Estradiol 4TI98Z838E

Types de publication

Multicenter Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

467-476

Subventions

Organisme : Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Organisme : Italian Ministry of Health, Rome
ID : ICH-NGS 05C202_2012

Informations de copyright

© The Author(s) 2023. Published by Oxford University Press on behalf of European Society of Endocrinology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Déclaration de conflit d'intérêts

Conflicts of interest: The authors have no conflict of interest to declare.

Auteurs

Giulia Rodari (G)

Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.
Endocrinology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

Silvia Federici (S)

Department of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy.
Department of Endocrine and Metabolic Diseases, IRCCS Istituto Auxologico Italiano, Milan, Italy.

Tommaso Todisco (T)

Endocrinology Unit, University-Hospital Pediatric Department, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.

Graziamaria Ubertini (G)

Endocrinology Unit, University-Hospital Pediatric Department, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.

Alessandro Cattoni (A)

Pediatric Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy.
Department of Medicine and Surgery, Milano-Bicocca University, Milan, Italy.

Marta Pagano (M)

Pediatric Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy.
Department of Medicine and Surgery, Milano-Bicocca University, Milan, Italy.

Federico Giacchetti (F)

Endocrinology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

Eriselda Profka (E)

Endocrinology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

Valeria Citterio (V)

Department of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy.

Dario Messetti (D)

Department of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy.

Valentina Collini (V)

Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.

Davide Soranna (D)

Biostatistics Unit, IRCCS Istituto Auxologico Italiano, Milan, Italy.

Erika Carbone (E)

Department of Endocrine and Metabolic Diseases, IRCCS Istituto Auxologico Italiano, Milan, Italy.

Maura Arosio (M)

Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.
Endocrinology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

Giovanna Mantovani (G)

Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.
Endocrinology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

Luca Persani (L)

Department of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy.
Department of Endocrine and Metabolic Diseases, IRCCS Istituto Auxologico Italiano, Milan, Italy.

Marco Cappa (M)

Research Unit for Innovative Therapies in Endocrinopathies, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.

Marco Bonomi (M)

Department of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy.
Department of Endocrine and Metabolic Diseases, IRCCS Istituto Auxologico Italiano, Milan, Italy.

Claudia Giavoli (C)

Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.
Endocrinology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH